293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797630849254948864 |
|---|---|
| author | Prashant R Nambiar Nicole A Protheroe Kelly DellaGrotte Harini Kantamneni Sumati Sundaram Scott F Heller Christina Ferren Collin Walter Corinne Decker Alison Crawford Tina Chang Albershardt |
| author_facet | Prashant R Nambiar Nicole A Protheroe Kelly DellaGrotte Harini Kantamneni Sumati Sundaram Scott F Heller Christina Ferren Collin Walter Corinne Decker Alison Crawford Tina Chang Albershardt |
| author_sort | Prashant R Nambiar |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:13:45Z |
| format | Article |
| id | doaj.art-b0fd247e17bd462799e3a3d712c32190 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:13:45Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-b0fd247e17bd462799e3a3d712c321902023-11-11T11:00:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0293293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancerPrashant R Nambiar0Nicole A Protheroe1Kelly DellaGrotte2Harini Kantamneni3Sumati Sundaram4Scott F Heller5Christina Ferren6Collin Walter7Corinne Decker8Alison Crawford9Tina Chang Albershardt10bluebird bio Inc, Cambridge, Massachusetts, USA12seventy bio, Cambridge, MA, USA12seventy bio, Cambridge, MA, USA12seventy bio, Cambridge, MA, USA12seventy bio, Cambridge, MA, USA12seventy bio, Cambridge, MA, USA12seventy bio, Cambridge, MA, USA12seventy bio, Cambridge, MA, USA2Regeneron Pharmaceuticals, Tarrytown, NY, USA2Regeneron Pharmaceuticals, Tarrytown, NY, USA12seventy bio, Cambridge, MA, USA |
| spellingShingle | Prashant R Nambiar Nicole A Protheroe Kelly DellaGrotte Harini Kantamneni Sumati Sundaram Scott F Heller Christina Ferren Collin Walter Corinne Decker Alison Crawford Tina Chang Albershardt 293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer Journal for ImmunoTherapy of Cancer |
| title | 293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer |
| title_full | 293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer |
| title_fullStr | 293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer |
| title_full_unstemmed | 293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer |
| title_short | 293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer |
| title_sort | 293 development of a muc16 specific car t cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer |
| work_keys_str_mv | AT prashantrnambiar 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT nicoleaprotheroe 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT kellydellagrotte 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT harinikantamneni 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT sumatisundaram 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT scottfheller 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT christinaferren 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT collinwalter 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT corinnedecker 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT alisoncrawford 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer AT tinachangalbershardt 293developmentofamuc16specificcartcellexhibitingpotentantitumoractivityforthetreatmentofpatientswithrecurrentovariancancer |